Wall Street got a sharp reminder this month of how fast sentiment can turn. Last Thursday the S&P 500 lost 4.4%, its worst day since April 2025, after midterm election results raised fears that regulation could hurt the AI trade. The Nasdaq Composite fell into correction territory, roughly 11% below the record it set in early October.
A rally on lower oil prices offered some relief at the start of this week. Then inflation data reopened the wound. Consumer prices rose 0.4% in October, the third straight monthly gain of at least that size and a touch above the 0.3% economists had expected. The stock market was still nervous from the prior week’s rout, and it showed. The S&P 500 fell 0.38% to 7,520.93, the Dow lost 0.30% and the Nasdaq Composite slid 0.74% on the news.
Inflation Revives Talk of Fed Rate Hikes
Federal Reserve Governor Christopher Waller said the central bank should raise interest rates in December and consider a half-point increase if inflation worsens. Dallas Fed President Lorie Logan went further, saying at least two more quarter-point hikes are needed to bring prices under control. Three straight monthly gains of 0.4% or more is the kind of streak that keeps rate-hike talk alive.
Traders have taken the message seriously. They now price roughly an 84% chance of a quarter-point December hike, after a week in which both the stock and bond markets swung hard.
Investors tracking how far some AI stocks have fallen can find more names in our ranking of oversold AI stocks that analysts see rebounding by more than half.
Chip Stocks Absorb the Heaviest Selling
Technology shares have taken the brunt of it. Selling in semiconductor stocks reached its most extreme level since 2019 earlier this week, by Yahoo Finance‘s measure, as worries about regulation of the AI trade added to the pressure.
Wednesday brought a rebound. The S&P 500 climbed 1.31% to 7,619.38, the Nasdaq Composite gained 1.60%, and the Dow rose 0.49%. The Nasdaq Composite had slipped into correction territory only days earlier. One day of gains does not erase the damage from the prior week, and the inflation and rate questions behind the selloff are still open. The Dow finished the day at 52,486.49.
Investors comparing cheaper alternatives can start with our roundup of affordable stocks that Wall Street analysts favor.
For now, the Federal Reserve’s December meeting is the date traders are watching, with a hike priced as the likely outcome.
Photo by Arturo Añez on Unsplash
Our Methodology
To compile this list, we reviewed analyst rating downgrades announced on Wednesday, November 11, 2026, from established Wall Street research firms. We have ranked these stocks in ascending order of their average upside potential, based on analysts’ average price target, as of November 11. We also list each stock’s number of hedge fund holders as of Q2 2026, from our database of 1,006 hedge funds.
At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
Sell Alert: 10 Stocks Analysts Downgraded on Wednesday
10. Surgery Partners (NASDAQ:SGRY)
Average Upside Potential: -8%
Number of Hedge Fund Holders: 30
Mizuho cut Surgery Partners to Neutral from Outperform on November 11 and raised its price target to $25 from $19, which matches the cash price in the pending buyout. The downgrade follows third-quarter results and a revised offer from HealthSpan Partners. A rival bid of $28 a share arrived, but the board kept backing the amended HealthSpan deal, citing a greater certainty of closing and lower regulatory risk.
Bain Capital owns about 39% of the shares and has agreed to vote for the HealthSpan transaction. Given that support and the board’s recommendation, Mizuho expects shareholders to approve it. The firm also called the deal price a fair multiple of its 2027 adjusted EBITDA estimate for the business, and it updated its estimates through 2028 alongside the call. A special committee unanimously recommended the amended deal.
Surgery Partners runs outpatient surgery centers, and its stock surged when the first offer surfaced. The company has cancelled its forward guidance, so the transaction, expected to close in the first quarter of 2027, now drives the shares. We covered what to expect next after that surge in an earlier piece.
9. Pediatrix Medical Group (NYSE:MD)
Average Upside Potential: -4%
Number of Hedge Fund Holders: 15
Pricing growth at Pediatrix Medical Group slowed to 0.3% in the third quarter from about 4% in each of the two before it. Mizuho took that as a warning. On November 11 the firm cut the stock to Underperform from Neutral and held its price target at $28. It argued that pricing gains have largely plateaued, which limits further upside to earnings per share. Healthcare services stocks have historically traded on volumes, Mizuho added.
Mizuho also pointed to the company’s heavy exposure to the birth rate, a factor management cannot control. With inflation running hot and low birth rates expected, the firm sees little room for a meaningful volume recovery and expects Pediatrix volume growth to lag overall healthcare use.
Pediatrix provides neonatal and maternal-fetal physician services. It still reported adjusted earnings of $0.72 per share for the quarter and raised the floor of its full-year EBITDA outlook. A favorable mix of insurance payers has more than offset weak volumes this year. Our look at how earnings kept growing while patient volumes kept falling covers the setup behind this debate.
8. Hartford Insurance Group (NYSE:HIG)
Average Upside Potential: 6%
Number of Hedge Fund Holders: 51
Wells Fargo moved Hartford Insurance Group to Equal Weight from Overweight on November 11 and trimmed its price target to $139 from $158. The call lands as investors weigh a third-quarter report in which commercial results softened. Core earnings per share fell from a year earlier, and a gain from ending an asbestos and environmental reinsurance contract lifted net income well above that core figure.
Attention has centered on the Middle & Large commercial unit, where the underlying combined ratio rose to 99.5% from 91.4% on higher workers’ compensation claim frequency and property losses. Catastrophe losses also climbed, while the Small Business unit improved.
Hartford sells business insurance, personal insurance and employee benefits. Its Equitable employee-benefits acquisition closed in October, and management raised the dividend alongside the report. The company is also changing leaders: Christopher Swift is the current chief executive, and President Mo Tooker is the named successor. That one-time gain makes the headline profit look stronger than the underlying business did. Investors are now watching whether commercial margins stabilize as that handover and the integration of the new benefits business proceed.
7. Mid-America Apartment Communities (NYSE:MAA)
Average Upside Potential: 12%
Number of Hedge Fund Holders: 30
Morgan Stanley analyst Adam Kramer downgraded Mid-America Apartment Communities to Equal Weight from Overweight on November 11 and cut his price target to $134 from $147. The bank first upgraded the stock in early 2025, betting that Sun Belt apartment fundamentals would recover once new supply cooled. Kramer says that recovery keeps getting pushed out, which keeps lowering expectations for new-lease rents, same-store revenue and funds from operations per share.
He still calls the company high quality and says its valuation looks inexpensive against private-market transaction values, and probably on a funds from operations multiple too. Morgan Stanley also now holds more balanced preferences across apartments, single-family rentals and manufactured housing.
The latest report shows the problem. Mid-America owns apartment communities across the Sun Belt. It met its own core funds from operations expectation but narrowed its full-year guidance, and new-lease pricing fell 6.0%. Management expects new-lease rates to improve from a year earlier in the fourth quarter, slightly later than it had planned, and cited higher interest rates. It said October blended rates improved by more than 100 basis points.
6. Toast (NYSE:TOST)
Average Upside Potential: 14%
Number of Hedge Fund Holders: 74
Bernstein analyst Harshita Rawat downgraded Toast to Market Perform from Outperform on November 11 and lowered her price target to $38 from $45. Rawat says one of the biggest reasons behind Bernstein’s February upgrade has already played out: the view that Toast would be an AI winner rather than a loser. She is now watching competition and the cost of growth more closely, and she called the chief financial officer’s coming exit not ideal.
Toast sells point-of-sale software and payment processing to restaurants. Its third-quarter report still looked solid, with new locations added, new AI products called Toast IQ Grow and Toast IQ Team, and a raised full-year outlook. Rawat’s February upgrade had come after software and fintech stocks de-rated sharply. The shares slid after the report, though, because annualized recurring revenue growth eased to 24% from 26% two quarters earlier.
Chief Financial Officer Elena Gomez is stepping down, and Michael Senno is set to succeed her. Analyst price targets on the stock still span a wide range, a sign that views remain divided. For more on the software push, see our look at whether Toast can defend its software upsell.
5. Halozyme Therapeutics (NASDAQ:HALO)
Average Upside Potential: 17%
Number of Hedge Fund Holders: 38
Halozyme reported a strong quarter, raised its full-year guidance, and then watched Morgan Stanley downgrade it. On November 11 analyst Sean Laaman moved the stock to Equal-Weight from Overweight while lifting the price target to $109 from $105. Laaman says the royalty base is diversifying and that Halozyme’s European patent position strengthened materially in October. After the pullback, he adds, the shares trade roughly in line with Morgan Stanley’s base-case value.
The sticking point is timing. The bank’s discounted cash flow value reflects today’s royalty portfolio, which peaks in 2029 when scheduled royalty-rate step-downs take effect. More value depends on a technology called Hypercon, a new antibody-drug conjugate opportunity and the next wave of launches using Halozyme’s ENHANZE delivery technology. The bank says it will count those more fully as they mature.
Halozyme collects royalties on injectable versions of cancer and immune drugs. Johnson & Johnson’s Darzalex, argenx’s Vyvgart Hytrulo and Roche’s Phesgo drive much of that income. Third-quarter revenue rose 39% to $493 million, and guidance moved higher. We also examined the large bet the company made on itself earlier this year.
4. Life360 (NASDAQ:LIF)
Average Upside Potential: 29%
Number of Hedge Fund Holders: 10
Advertising revenue at Life360 came in at $25 million in the third quarter, short of both BofA Securities’ estimate and the Street’s. The firm downgraded the stock on November 11. The Nativo acquisition lifted advertising sharply from a year earlier, yet BofA wants faster monetization. BofA moved Life360 to Neutral from Buy and cut its price target to $45 from $60. It sees no material acceleration in the fourth quarter or in 2027 from the Pet Tracker, Uber or Nativo initiatives. It stays constructive on them over the longer term.
BofA lowered its 2027 revenue and EBITDA estimates, citing weaker advertising and higher sales and marketing spending. At about 19 times 2027 enterprise value to EBITDA, it considers the valuation fair, because strong subscription growth is offset by slower ad monetization.
Life360 sells subscription plans for its family location and safety app. Results were otherwise strong. The company raised its full-year revenue and EBITDA guidance. Management cautioned that US paying-circle growth could slow after recent price increases. Chief Executive Officer Lauren Antonoff said early results from the changes are encouraging.
3. Akamai Technologies (NASDAQ:AKAM)
Average Upside Potential: 50%
Number of Hedge Fund Holders: 62
Evercore ISI downgraded Akamai Technologies to In-Line from Outperform on November 11 and cut its price target to $90 from $150. The firm cites financing concerns and a complex investment cycle, and says the recent financing adds complexity and raises the need for execution. Evercore expects the shares to stay range-bound until the third or fourth quarter of 2027. By then, it says, operating margins should begin to stabilize, Anthropic revenue should be ramping and a path to positive free cash flow should be clearer. It remains constructive on the underlying opportunity.
Akamai topped consensus estimates for third-quarter revenue and adjusted earnings per share. Investors have focused instead on the spending needed to build its cloud business. The company is known for delivering and securing web traffic and now sells cloud computing. Management says it has signed more than $14 billion of multi-year commitments in that business this year. GAAP operating margin fell to 10% in the third quarter as spending rose.
The Anthropic agreement is the largest piece of that backlog, and our piece on the Anthropic deal covers how it came together.
2. Riot Platforms (NASDAQ:RIOT)
Average Upside Potential: 79%
Number of Hedge Fund Holders: 55
Riot Platforms keeps signing leases at a pace few bitcoin miners can match, and Keefe, Bruyette & Woods still moved it to Market Perform from Outperform on November 11. The firm raised its price target to $23 from $20. Investors are focused on how Riot will pay for what it has promised. The company signed a long-term lease at its Corsicana, Texas, site with an unnamed frontier AI lab worth about $28 billion in total. It plans roughly $5.5 billion of non-recourse financing without issuing new equity.
Delivery at Corsicana begins late next year. The build still has to be funded and finished. Chief Executive Officer Jason Les leads the company. Riot is a bitcoin miner converting its Texas sites into data centers for AI. It also has an earlier lease with Anthropic at its Rockdale site. Mining revenue fell in the third quarter as the average bitcoin price dropped.
The company reported a small third-quarter profit against a consensus loss, so the debate centers on funding rather than demand. We looked at whether Riot can fund its data center build after the earlier lease was announced.
1. Nvidia (NASDAQ:NVDA)
Average Upside Potential: 83%
Number of Hedge Fund Holders: 285
A report that Nvidia’s board is weighing the removal of founding Chief Executive Officer Jensen Huang hit the stock hard this week, and Baird downgraded it on November 11. The firm moved Nvidia to Neutral from Outperform and cut its price target to $200 from $500. Baird cites reduced visibility into data center demand for 2027, mostly tied to supply limits, plus uncertainty over US government action on China sales and over the CEO’s tenure. It expects the shares to stay in a trading range.
Baird says hyperscaler capital spending growth could slow to about 40% in 2027. It adds that demand for Nvidia’s latest chips still outpaces supply, but some preemptive orders could be cut. On leadership, the firm wrote, “The odds of CEO transition are increasing into 2027.” Morgan Stanley also removed Nvidia from its top-pick list this week.
Nvidia designs the chips that power AI data centers. Results are due next Tuesday after the close, with analysts expecting earnings of $2.47 a share. Our analysis of why Nvidia trades as if growth will stop covers the valuation side.
READ NEXT: Nvidia (NVDA) Grows Like a Rocket But Still Looks Cheap and Akamai (AKAM) Wants to Be the Bouncer for Your AI Agents
